Form 4: Nuvation Bio Inc. Director Cui Xiangmin Increases Stake in Company

Director Cui Xiangmin reports multiple purchases of Nuvation Bio Inc. (NUVB) Class A Common Stock through associated investment funds.

Summary

• Cui Xiangmin, a director of Nuvation Bio Inc. (NUVB), has reported several transactions involving the acquisition of Class A Common Stock.
• These transactions occurred between June 20, 2024, and June 24, 2024.
• The shares were purchased indirectly through entities such as Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital China Life Sciences USD Fund III, L.P., and Decheng Anbio Limited.
• The purchases were made at prices ranging from $2.90 to $3.00 per share.
• Following these transactions, the total number of shares beneficially owned by these entities is substantial.
• Cui Xiangmin disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects insider buying, which is generally positive, but the disclaimers of beneficial ownership temper the enthusiasm.

Positives

• The director's indirect purchase of shares may signal confidence in the company's future prospects.
• Increased ownership by associated funds could provide additional stability to the stock.

Risks

• The director disclaims beneficial ownership except to the extent of his pecuniary interest, which could limit the significance of these transactions as a direct indicator of his confidence.
• The transactions are conducted through investment funds, so they may be driven by fund-specific strategies rather than solely by the director's view of Nuvation Bio's prospects.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders may view the director's indirect purchases as a positive signal.
• The increased stake held by associated funds could influence the company's strategic decisions.

Key Dates